As of Tuesday, December 09, Cartesian Therapeutics, Inc.’s RNAC share price has surged by 7.59%, which has investors questioning if this is right time to sell.
The use of Cartesian and six-axis robots, as well as selective-compliance-articulated robot arms (SCARAs) is on the rise. They automate tasks to accelerate cycle times, increase throughput, and ...
Selecta Biosciences is jumping into Cartesian’s cell therapy cockpit, preparing to take flight once again after landing nearly all of its previous programs. The two companies announced a reverse ...
Astellas is putting the kibosh on a licensing deal with Cartesian Therapeutics, deciding it’s no longer interested in using the latter’s Xork asset to help treat Pompe disease. The decision disclosed ...
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month follow-up ...
Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash. Cartesian Therapeutics, Inc. has announced the ...
NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the pricing of its initial public offering of 24,000,000 units, upsized from 20,000,000 units, at a price of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback